A first-in-human, Phase 1a clinical trial of GMI-1687 in healthy volunteers
Latest Information Update: 01 Jul 2025
At a glance
- Drugs GMI 1687 (Primary)
- Indications Inflammation; Vaso-occlusive crisis
- Focus Adverse reactions; First in man
- Sponsors Crescent Biopharma; GlycoMimetics
Most Recent Events
- 16 Jun 2025 According to a Crescent Biopharma media release, GlycoMimetics has been merged with Crescent Biopharma. The combined company will operate under the name Crescent Biopharma.
- 04 Jan 2024 According to a GlycoMimetics media release, data analysis is ongoing, with full study results to be presented at an upcoming medical meeting.
- 04 Jan 2024 Results presented in a GlycoMimetics media release.